Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Buenos Aires - Delayed Quote ARS

Gilead Sciences, Inc. (GILD.BA)

Compare

35,000.00

+775.00

+(2.26%)

At close: February 28 at 4:59:46 PM GMT-3

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 15 hours ago

GILD
Wall Street Bulls Look Optimistic About Gilead (GILD): Should You Buy?

According to the average brokerage recommendation (ABR), one should invest in Gilead (GILD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks 15 hours ago

GILD
Drug Stocks Are the New Safe Bet in a Shaky Market

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

The Wall Street Journal 18 hours ago

AMGN

ABBV

AZN
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks yesterday

GILD
Patient Insight Institute announces partnership to improve cancer screening

The collaboration aims to create a patient-driven screening method focused on trust and human interaction.

Hospital Management yesterday

GILD
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

BLUE and GILD are in the spotlight this week on key updates.

Zacks 2 days ago

BMRN

GILD

TRDA
The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant

Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant are included in this Analyst Blog.

Zacks 2 days ago

MDT

SCHW

GILD
Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors have been highlighted in this Screen of The Week article.

Zacks 2 days ago

SYF-PB

GILD

EXEL
Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic

Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corporation (SCHW), Gilead Sciences, Inc. (GILD) and Medtronic plc (MDT), as well as two micro-cap stocks Cooper-Standard Holdings Inc. (CPS) and Rave Restaurant Group, Inc. (RAVE).

Zacks 3 days ago

MDT

GILD

RAVE
Morgan Stanley sees FDA approval of GILD's Lenacapavir

Investing.com -- Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ:GILD)' Lenacapavir (LEN) for HIV prevention (PrEP) on or before its June 19 PDUFA date, a move that the bank believes could drive upside for GILD shares.

Investing.com 3 days ago

GILD
4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty

Here are four PEG-based GARP picks, GILD, EXEL, SYF and TAP, which qualify our screening criteria.

Zacks 3 days ago

GILD

SYF-PB

TAP-A
Gilead’s lenacapavir applications for HIV gain EMA validation

The applications are backed by data from the company-conducted Phase III trials.

Pharmaceutical Technology 3 days ago

GILD
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

FOSTER CITY, Calif., February 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s Marketing Authorization Application (MAA) and EU-Medicines for all (EU-M4all) application for lenacapavir—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Business Wire 4 days ago

GILD
Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other Renaissance Technologies portfolio’s top stock picks. The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its investment […]

Insider Monkey 5 days ago

GILD
Gilead’s lenacapavir under priority review could revolutionise HIV PrEP

The HIV-1 capsid inhibitor is already marketed in the US and EU under the brand name Sunlenca.

Clinical Trials Arena 7 days ago

GILD

GLDAF
Some Investors May Be Willing To Look Past Gilead Sciences' (NASDAQ:GILD) Soft Earnings

Gilead Sciences, Inc.'s ( NASDAQ:GILD ) recent soft profit numbers didn't appear to worry shareholders, as the stock...

Simply Wall St. 7 days ago

GILD
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

FOSTER CITY, Calif., February 20, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. Seladelpar (an orphan designated product) is now approved and will provide an important treatment

Business Wire 8 days ago

GILD
GILD or VRTX: Which Is the Better Value Stock Right Now?

GILD vs. VRTX: Which Stock Is the Better Value Option?

Zacks 8 days ago

VRTX

GILD
Gilead Sciences, Inc. (GILD): Among Stocks That Analysts Think Will Go Up

We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other stocks that analysts think will go up. The S&P 500 index touched an all-time high this week as Mark Zuckerberg’s company’s 20-day […]

Insider Monkey 8 days ago

GILD
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

Here is how Gilead Sciences (GILD) and Natera (NTRA) have performed compared to their sector so far this year.

Zacks 8 days ago

GILD

Performance Overview

Return	GILD.BA	S&P 500
YTD	+28.68%	+1.24%
1-Year	+80.66%	+17.45%
3-Year	+1,037.24%	+36.14%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Gilead Sciences, Inc. (GILD.BA)

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Wall Street Bulls Look Optimistic About Gilead (GILD): Should You Buy?

Drug Stocks Are the New Safe Bet in a Shaky Market

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Patient Insight Institute announces partnership to improve cancer screening

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic

Morgan Stanley sees FDA approval of GILD's Lenacapavir

4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty

Gilead’s lenacapavir applications for HIV gain EMA validation

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks

Gilead’s lenacapavir under priority review could revolutionise HIV PrEP

Some Investors May Be Willing To Look Past Gilead Sciences' (NASDAQ:GILD) Soft Earnings

Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

GILD or VRTX: Which Is the Better Value Stock Right Now?

Gilead Sciences, Inc. (GILD): Among Stocks That Analysts Think Will Go Up

Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

Performance Overview